ARTICLE | Finance
Ebb & Flow
September 1, 2003 7:00 AM UTC
Like CancerVax, which filed on Aug. 14, Myogen only waited one day to file for its IPO after raising $40 million in a tranche of a series D top-off round. According to the prospectus, the latest financing values Myogen around $250 million. The series D garnered a total of $106.4 million.
Myogen markets Perfan I.V. enoximone in Europe for acute decompensated heart failure and has a capsule formulation in Phase III testing in congestive heart failure...